Annual balance sheet for Sagimet Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 56.7 | 32.3 | 94.9 | 151 | 113 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 58.7 | 32.8 | 96.6 | 153 | 116 |
| Net Property, Plant And Equipment | 0.342 | 0.212 | 0.073 | 0.077 | 0.078 |
| Long Term Investments | |||||
| Total Assets | 59 | 33 | 96.7 | 160 | 116 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.44 | 5.28 | 5.65 | 4.45 | 5.1 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2.67 | 5.36 | 5.65 | 4.45 | 5.1 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 56.4 | 27.7 | 91.1 | 156 | 111 |
| Total Liabilities & Shareholders' Equity | 59 | 33 | 96.7 | 160 | 116 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |